Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 26Burkitt Lymphoma 22Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, B-Cell 7Lymphoma 5Recurrence 4Lymphoma, Large B-Cell, Diffuse 4Leukemia 4Lymphoma, Non-Hodgkin 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Philadelphia Chromosome 1Neoplasm, Residual 1Lymphoma, Follicular 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Blast Crisis 1

Interventions

Cyclophosphamide 87fludarabine 77fludarabine phosphate 45Tacrolimus 45Whole-Body Irradiation 42Mycophenolic Acid 42Busulfan 35Melphalan 32Antilymphocyte Serum 24Methotrexate 23thymoglobulin 22Standard of Care 22Rituximab 22venetoclax 20Thiotepa 20Sirolimus 20Azacitidine 20Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 17Cytarabine 16Bortezomib 16Nivolumab 15Filgrastim 15Specimen Handling 14Dexamethasone 14Blood Specimen Collection 14Cyclosporine 13Surveys and Questionnaires 12Mesna 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Inotuzumab Ozogamicin × Clear all
NCT04307134 2025-12-31

Besponsa Post Marketing Surveillance Study

Pfizer

Completed
108 enrolled 39 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hematologic Neoplasms

NCT01664910 2024-07-23

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Completed
27 enrolled 12 charts
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡